3、Li C, Ren C, Wen L, et al. Heterogenous and Low Expression of HER2 in Breast Cancer Overcome by DS-8201a in a Heavily Treated Patient: Case Report and Review of the Literature. Clin Med Insights Oncol. 2022;...
这是继2023年2月首次在华获批单药治疗既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者后,新一代ADC药物德曲妥珠单抗在中国获批的又一重磅适应症。 该获批疗法为国内首个有助于HER2低表达转移性乳腺癌患者延缓疾病进展...
1. ADC Drug DS-8201 Shows Strong Efficacy in Patients with Low HER2 Breast Cancer Expression – Creative Biolabs ADC Blogcreative-biolabs.com/bl2. Global Phase II Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer Initiated » ADC Reviewadcreview.com/news/glob3. Keam...
“HER2-targeted treatments historically have not been effective in treating metastatic breast cancer with low levels of HER2 expression,” said Hiroji Iwata, MD, PhD, Vice Director and Chief of Breast Oncology at Aichi Cancer Center Hospital, Nagoya, Japan. “While these results of DS-8201 in ...
Background: HER2-targeted therapies have improved survival for advanced HER2-positive breast cancers (BC), but none have been approved for tumors with low levels of HER2 expression (ie, HER2 IHC 1+ or 2+/ISH-negative). Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody-...
(a) T-DM1-treated HER2 positive breast cancer(IHC3+,or ISH+)(b) Trastuzumab-treated HER2-positve gastric cancer(IHC3+)(c) HER2-low breast cancer(IHC2+/ISH-)(d) HER2-expressionor HER2-mutated solid tumor(IHC1+,IHC2+,IHC3+)(e) HER2-positive or HER2-low breast cancer(IHC1+,IHC2...
HER2靶向治疗首次写入2022v4版NSCLC NCCN指南,推荐使用DS-8201和恩美曲妥珠单抗!2022.v4 NCCN临床实践指南:非小细胞肺癌.pdf286页 内容提供方:科研立项/文案设计/翻译润色/PPT制作 大小:2.46 MB 字数:约165.65万字 发布时间:2022-09-05发布于山东 浏览人气:29...
Updated analysis from ongoing phase 1 study of [fam-] trastuzumab deruxtecan (DS-8201) demonstrated a confirmed overall response rate of 15.8 percent and a disease control rate of 84.2 percent in 19 evaluable patients with heavily pretreated colorectal cancer with varying levels of HER2 expression...
TPS1102 Background: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have greatly improved survival in HER2+ breast cancer (BC). However, there are many more BC patients with HER2-low expression (immunohistochemistry [IHC] 1+ or 2+/ in situ hybridization-negative), for whom ...
通过现有HER2检测方法确定为HER2低表达乳腺癌患者将有机会接受Enhertu的治疗,抗HER2的靶向治疗获益人群从15%(HER2阳性)进一步扩大至60~70%(HER2阳性+低表达)。 ▲乳腺癌中HER2表达的分布情况 什么是HER2低表达乳腺癌 HER2低表达乳腺癌(HER2-low BC)被定义为乳腺癌细胞表面含有较低水平的HER2蛋白。HER2低表达乳腺癌...